title: Imatinib, cytokines and interstitial lung disease in a patient with primary myelofibrosis.
authors.forename: Bruno
authors.initials: B
authors.lastname: Robibaro
authors.forename: Anna
authors.initials: A
authors.lastname: Kropfmueller
authors.forename: Mathias
authors.initials: M
authors.lastname: Prokop
authors.forename: Paul
authors.initials: P
authors.lastname: Haber
authors.forename: Heinz
authors.initials: H
authors.lastname: Gisslinger
mesh_terms: D001549:Benzamides; D016207:Cytokines / Q000276:immunology*; D006801:Humans; D000068877:Imatinib Mesylate; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000209:etiology / Q000276:immunology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D055728:Primary Myelofibrosis / Q000150:complications / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D001549:Benzamides; D016207:Cytokines; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate